What Mounjaro looks like — and why it matters

The KwikPen: what you're actually holding

The Mounjaro KwikPen is a cylindrical, reusable-style auto-injector roughly the size of a thick marker pen. The body is predominantly white or off-white plastic, with a coloured label band that identifies the strength. The cartridge window near the base lets you see the remaining liquid, it should be clear to slightly yellow and free of particles or cloudiness. A grey rubber cap covers the needle end; you attach a fresh needle before each injection and dispose of it immediately after. One box, one pen, four doses: that's the design.

The outer carton is roughly credit-card-sized in footprint and printed in English with the strength prominently on the front. On a dispensed prescription, your pharmacy's label sits on the box alongside the dispensing date, your name, and the prescriber's instructions. If any of that information is missing or looks printed on an inkjet at home, treat it as a red flag. The full visual breakdown of the KwikPen covers each component in detail, including what the needle assembly looks like and how the dose counter works.

One quick check you can do in under a minute: hold the pen up to a light source and look through the cartridge window. Genuine tirzepatide solution is clear. Cloudy liquid, visible particles, or an unusual colour are grounds to contact the pharmacy before injecting anything.

The six strengths and how they differ visually

Treatment begins at 2.5 mg and is stepped up by the prescriber (usually in four-week intervals) through 5 mg, 7.5 mg, 10 mg, 12.5 mg, and up to 15 mg. Each strength's label uses a distinct colour scheme, which is deliberate: it reduces the risk of picking up the wrong pen by habit. The dose is also printed in large text on both the box and the pen body. When your prescription changes strength, your next delivery will arrive in different-coloured packaging. That change is expected and normal; it does not mean something has gone wrong.

The clinical rationale for the stepwise schedule is worth understanding. The 2.5 mg starting dose exists to let your system adjust, gastric emptying slows, appetite hormones shift, and starting gently reduces the severity of the nausea that can accompany those early weeks. The prescriber decides when and whether to increase; you'll find more on that process on the tirzepatide overview page, which covers the mechanism behind each step.

People who have transferred from another provider sometimes arrive with a pen at a higher dose. At nume, transfer patients are asked to provide evidence of their current treatment before any prescription is issued, partly for safety, partly because the dispensed pen needs to match the clinical record precisely.

Why the packaging question connects to a real safety decision

The MHRA has publicly warned about counterfeit weight-loss pens sold through social media and unverified online sellers. In October 2025, enforcement teams raided the first illicit UK manufacturing site producing fake tirzepatide pens. Fake pens have been found to contain insulin rather than tirzepatide, a substitution that can cause life-threatening hypoglycaemia in someone who isn't diabetic. This is the practical reason that Mounjaro is a prescription-only medicine: legitimate supply requires a prescriber, a GPhC-registered pharmacy, and a traceable supply chain.

The safest way to confirm any online pharmacy is real: look it up on the GPhC pharmacy register before you order. Sellers who offer tirzepatide without a prescription, via direct message, or at prices far below the current UK market are presenting exactly the risk profile the MHRA is warning about. If the packaging you receive looks unfamiliar or the pen behaves oddly on first use, contact the dispensing pharmacy before proceeding. Report anything suspicious via the MHRA's Yellow Card scheme.

For context on how UK private pricing works and what a legitimate prescription includes, the weight-loss treatments page sets out the process clearly.

Who can receive a Mounjaro prescription and what comes next

Mounjaro is licensed in the UK for adults with a BMI of 30 or above, or 27 and above where at least one weight-related condition is present, things like high blood pressure, high cholesterol, obstructive sleep apnoea, or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI alone isn't the whole picture; a prescriber assesses your full medical history, any medicines you take, and whether tirzepatide is appropriate for you specifically.

Pregnancy, breastfeeding, and actively trying to conceive are all situations where tirzepatide is not recommended. The same applies to anyone under 18. History of certain conditions (including medullary thyroid carcinoma or pancreatitis) requires careful prescriber consideration before treatment starts.

The Mounjaro information page goes deeper on eligibility and the conditions it's licensed to treat. If you're thinking about what starting treatment actually involves day to day (routines, what to eat alongside it, how others have structured their approach) the Mounjaro cookbook guide is a practical companion worth reading, and if you have questions about physical changes during treatment, our guide on whether Mounjaro makes you look older addresses what the evidence actually says. And if you're considering whether this is the right route for you, the weight-loss treatment overview lays out the full landscape of licensed options. When you're ready, check your eligibility with our prescribers, the consultation is free, and a qualified GPhC-registered prescriber, not software, reads every submission the same day.